ArticleBiomimetics (Basel, Switzerland)2025
Optimizing Biodegradable Poly(D,L-lactide) Scaffolds Reinforced with Graphene Oxide for Bone Tissue Regeneration.
Article in Biomimetics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study investigates the potential of porous poly(D,L-lactide) (PDLLA) scaffolds reinforced with graphene oxide (GO) for bone tissue engineering applications. Scaffolds were fabricated using thermally induced phase separation (TIPS) and characterized in terms of morphology, biodegradation, thermal and mechanical properties, and cytocompatibility. The incorporation of GO enhanced both mechanical strength and thermal stability, likely due to hydrogen bonding and electrostatic interactions between GO's functional groups (carbonyl, carboxyl, epoxide, and hydroxyl) and PDLLA chains. In vitro degradation studies showed that GO accelerated degradation, while scaffolds with higher GO content retained superior mechanical strength. Cytotoxicity assays confirmed the biocompatibility of all scaffold variants, supporting their suitability for biomedical applications. Overall, the findings demonstrate how GO incorporation can modulate scaffold composition and performance. This provides insights for the design of improved systems for bone tissue regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.